Full Year 2025 Cosmo Pharmaceuticals NV Earnings Call Transcript
Key Points
- Cosmo Pharmaceuticals NV (CMOPF) achieved a significant structural transformation in 2025, simplifying and aligning the organization around scalable platforms.
- The company reported a strong financial performance with revenue reaching EUR104.2 million, 85% of which is now recurring, and EBITDA of EUR9.5 billion.
- Cosmo Pharmaceuticals NV (CMOPF) has a robust pipeline with positive Phase 3 results for Clascoterone in androgenetic alopecia and ongoing trials in ulcerative colitis and bile acid diarrhea.
- The company achieved EU MDR certification for its MedTech AI platform, expanding its capabilities and reinforcing its durability in Europe.
- Cosmo Pharmaceuticals NV (CMOPF) maintains a strong balance sheet with EUR128.3 million in cash, zero debt, and a proposed dividend of EUR2.10 per share, reflecting confidence in its business strength.
- The company faces challenges in maintaining its recurring revenue growth, with project-based revenues significantly lower than the previous year due to the absence of Medtronic milestones.
- Operating expenses, particularly cost of sales, increased to EUR53.6 million, reflecting higher commercial volumes and product mix effects.
- There is uncertainty regarding the timing and structure of potential partnerships for Clascoterone, which is crucial for maximizing shareholder value.
- The company’s guidance for 2026 does not include potential revenue from pipeline development stage assets, indicating reliance on existing revenue streams.
- Cosmo Pharmaceuticals NV (CMOPF) faces competition and market noise, particularly in the dermatology space, with other companies developing similar products.
Ladies and gentlemen, welcome to the full-year 2025 results conference call and live webcast. I'm Mara, the chorus call operator. (Operator Instructions)
The conference is being recorded. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Giovanni Di Napoli, CEO. Please go ahead, sir.
Good morning, good afternoon, and welcome, everyone. I'm Giovanni Di Napoli, CEO of Cosmo; and I'm joined today by our CFO, Svetlana Sigalova. Thank you for being with us for 2025 full year results. We walk you through our performance, our progress on strategic priorities and the path ahead.
A quick note on forward-looking statements. 2025 was not a year of noise. It was a year of execution. Today, I want to walk you through three very clear messages. First, structural transformation has been delivered. Over the past year, we fundamentally reshaped Cosmo. We simplified, we focused
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
